Mission Therapeutics’ strategy is to create value by advancing its pipeline program through early clinical development, preferentially with a patient selection strategy to enhance the probability of demonstrating early signs of efficacy. Selected programs may be advanced in partnership with other pharmaceutical companies.
Through application of our DUB platform, we have the potential to explore multiple additional DUB targets relevant to other diseases, in strategic partnerships with other pharmaceutical companies or academics.
- Mission Therapeutics Appoints Dr Bobby Soni to its Board of Directors8th March 2018
- Mission Therapeutics Strengthens Senior Management Team with Appointment of Dr Paul Thompson, Vice President, Clinical Development1st March 2018
- Mission Therapeutics’ Highlights Positive Parkinson’s Disease USP30 Target and Inhibitor Data at the Society for Neuroscience 2017 Annual Meeting16th November 2017